What is Ilumya (tildrakizumab) for?

Ilumya (tildrakizumab) is a treatment for adults with plaque psoriasis. It helps those who need injections, pills, or light therapy. It’s a single-dose syringe with 100 mg/mL tildrakizumab.

How does Ilumya (tildrakizumab) work?

tildrakizumab is a protein that blocks IL-23 cytokines. These cytokines cause inflammation. They are linked to diseases like psoriasis.

By stopping IL-23, tildrakizumab reduces inflammation.

Where has Ilumya (tildrakizumab) been approved?

Ilumya was approved by:

• The Food and Drug Administration (FDA), USA on March 20, 2018.
• The European Medicines Agency (EMA), Europe on September 17, 2018 under the brand name Ilumetri.

It also got Orphan Drug designation for type 1 diabetes, Crohn’s disease, ulcerative colitis, and systemic lupus erythematosus.

It might be approved in other places too. If you’re unsure, contact our support team.

How is Ilumya (tildrakizumab) taken?

The standard dosage is:

• Starting dose: 100 mg at Weeks 0, 4
• Every twelve weeks (3 months) thereafter

For more details, see the official prescribing information in our references section.

Note: Please consult with your treating doctor for personalised dosing.

Are there any known adverse reactions or side effects of Ilumya (tildrakizumab)?

Common adverse reactions

The most common side effects include:

• upper respiratory infections
• Injection site reactions
• Diarrhea

Serious adverse reactions

The serious side effects include:

• Increased risk of infections (bacterial, fungal, and viral)

Use in a specific population

It’s not known if Ilumya harms fetuses. It’s advised to avoid pregnancy and breastfeeding.

Cibinqo (abrocitinib)